AI-Enabled Quantitative MRI Platform for Early Disease Assessment

A Hong Kong-developed medical-imaging venture is commercializing a patented, software-based enhancement for existing MRI systems. The technology enables faster, non-invasive quantitative assessment of tissue changes associated with chronic diseases, initially focusing on liver fibrosis, with potential applications in neurological and musculoskeletal conditions. The project has completed technical validation and is progressing through clinical and commercial development. It is seeking strategic investors, medical-imaging partners, healthcare operators and international commercialization partners to support clinical validation, regulatory development and global market expansion. Further information will be provided to qualified parties under appropriate confidentiality arrangements.